Prostate cancer patients' utilities for health states: How it looks depends on where you stand

Medical Decision Making

Volumn 18, Issue 3, 1998, Pages 278-286

  Chapman, Gretchen B ^a   Elstein, Arthur S ^b   Kuzel, Timothy M ^b   Sharifi, Roohollah ^b   Nadler, Robert B ^b   Andrews, Anita ^b   Bennett, Charles L ^b  

^a RUTGERS UNIVERSITY   (United States)

^b NONE

Author keywords

Decision making; Decision theory; Patient participation; Prostatic neoplasms

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DECISION MAKING; DECISION THEORY; ETHNIC GROUP; HEALTH STATUS; HUMAN; LONGEVITY; MAJOR CLINICAL STUDY; MALE; PATIENT; PROSTATE CANCER; QUALITY OF LIFE;

ACTIVITIES OF DAILY LIVING; AFRICAN AMERICANS; AGED; ATTITUDE TO HEALTH; CHOICE BEHAVIOR; EUROPEAN CONTINENTAL ANCESTRY GROUP; HEALTH STATUS; HUMANS; LONGEVITY; MALE; PILOT PROJECTS; PROSTATIC NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0031800857     PISSN: 0272989X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0272989X9801800304     Document Type: Article

References (44)

1. Cassileth BR, Seidmon EJ, Soloway MS, et al. Patients' choice of treatment in Stage D prostate cancer. Urology. 1989;33 suppl5:57-62.
2. Sox HC, Blatt MA, Higgins MC, Marton KI. Medical Decision Making. Boston, MA: Butter-worths, 1988.
3. Weinstein MC, Fineberg HV. Clinical Decision Analysis. Philadelphia, PA: W. B. Saunders, 1980.
4. Torrance GW. Social preferences for health states: an empirical evaluation of three measurement techniques. Socio-Econ Plan Sci. 1976;10:129-36.
5. Chodak GW. Screening and early detection of prostate cancer. Cancer. 1993;71:981-3.
6. G. Lange PH. Controversies in management of apparently localized carcinoma of the prostate. Urology. 1989;34suppl: 13-8.
7. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy: time trends, geographic variation, and outcomes. JAMA. 1993;269:2633-6.
8. Wasson JH, Cushman CC, Bruskewitz RC, et al. A structured literature review of treatment for localized prostate cancer. Arch Fam Med. 1993;2:487-93.
9. Coffey DS. Prostate cancer: an overview of an increasing dilemma. Cancer. 1993;71:880-6.
10. Eisenberger MA, Simon R, O'Dwyer PJ, et al. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol. 1985;3:827-41.
11. Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol. 1989;7:590-7.
12. Chodak GW, Thistead RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;321:419-24.
13. Johannson JE, Adami HO, Andersson SO, et al. High 10-year survival in patients with untreated prostate cancer. JAMA. 1992;267:2191-6.
14. Soloway MS, Chodak GW, Vogelzang NJ, Block NL, Schellhammer PF. Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Urology. 1991;37:46-51.
15. Cassileth BR, Soloway MS, Vogelzang NJ, et al. Quality of life and psychosocial status in stage D prostate cancer. Quality of Life Research. 1992;1:323-9.
16. Litwin MS, Hays RD, Fink A, et al. Measuring health related quality of life in men with prostate cancer. J Urol. 1995;152:1882-7.
17. Calais da Silva F, Reis E, Costa T, et al. Quality of life in patients with prostatic cancer. Cancer. 1993;1suppl:1138-42.
18. Fossa SD, Aaronson N, Newling D, et al. Quality of life and treatment of hormone resistant metastatic prostatic cancer. Eur J Cancer. 1990;1:1133-6.
19. Herr HW, Kornblith AB, Ofman UA. A comparison of the quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer. 1993;71suppl:1143-50.
20. Pedersen KV, Carlsson P, Rahmquist M, Varenhorst E. Quality of life after radical retropubic prostatectomy for carcinoma of the prostate. Eur Urol. 1993;4:7-11.
21. Singer PA, Tasch ES, Stocking C, Rubin S, Siegler M, Weischselbaum R. Sex or survival: trade-offs between quality and quantity of life. J Clin Oncol. 1991:9:328-34.
22. Cantor SB, Spann SJ, Volk RJ, Cardenas MP, Warren MM. Prostate cancer screening: a decision analysis. J Fam Pract. 1995;41:33-41.
23. Krahn MD, Mahoney JE, Eckman MH, Trachtenberg J, Pauker SG, Detsky AS. Screening for prostate cancer: a decision analytic view. JAMA. 1994;272:773-80.
24. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA. 1993;269:2650-8.
25. Krahn MD, Ritvo P, Naglie G, Irvine J, Magistretti A, Trachtenberg J. Patient and health professional quality of life ratings in the construction of an empirically derived, domain-linked utility instrument for prostate cancer [abstr]. Med Decis Making. 1996;16:470.
26. Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis. 1987;40:593-600.
27. Janis IL, Mann L. Decision Making: A Psychological Analysis of Conflict, Choice and Commitment. New York: Free Press-Macmillan, 1977.
28. Boyd NF, Sutherland HJ, Heasman KZ, Tritchler DL, Dummings BJ. Whose utilities for decision analysis? Med Decis Making. 1990;10:58-67.
29. Sackett DL, Torrance GW. The utility of different health states as perceived by the general public. J Chronic Dis. 1978;31:697-704.
30. Ashby J, O'Hanlon M, Buxton MJ. The time trade-off technique: how do the valuations of breast cancer patients compare to those of other groups? Quality of Life Research. 1994;3:257-65.
31. Llewellyn-Thomas HA, Sutherland HJ, Theil EC. Do patients' evaluations of a future health state change when they actually enter that state? Med Care. 1993;31:1002-12.
32. Hays RD, Siu AL, Keeler E, et al. Long-term care residents' preferences for health states on the quality of well-being scale. Med Decis Making. 1996;16:254-61.
33. Bennett CL, Matchar D, Crawford D. Cost-effectiveness models of flutamide: are they helpful to policy-makers? Cancer. 1996;9:1854-61.
34. Glasziou PP, Bromwich S, Simes RJ. Quality of life six months after myocardial infarction treated with thrombolytic therapy. Med J Aust. 1994;161:532-6.
35. Stiggelbout AM, Kiebert GM, Kievit J, Leer JWH, Habbema JDF, deHaes JCJM. The utility of the time trade-off method in cancer patients: feasibility and proportional trade-off. J Clin Epidomiol. 1995;48:1207-14.
36. Stiggelbout AM, deHaes JCJM, Kiebert GM, Kievet J, Leer JWH. Tradeoffs between quality and quantity of life: development of the QQ Questionnaire for cancer patient attitude. Med Decis Making. 1996;16:184-92.
37. O'Leary JF, Fairclough DL, Jankowski MK, Weeks JC. Comparison of time-tradeoff utilities and rating scale values of cancer patients and their relatives: evidence for a possible plateau relationship. Med Decis Making. 1995;15:132-7.
38. Mazur DJ, Merz JF. Older patients' willingness to trade off urologic adverse outcomes for a better chance at five-year survival in the clinical setting of prostate cancer. J Am Geriatr Soc. 1995;43:979-84.
39. Katz JN, Phillips CB, Fossel AH, Liang MH. Stability and responsiveness of utility measures. Med Care. 1994;32:183-8.
40. Tsevat J, Solzan JG, Kuntz KM, et al. Health values of patients infected with human immunodeficiency virus: relationship to mental health and physical functioning. Med Care. 1996;34:44-57.
41. Llewellyn-Thomas H, Sutherland HJ, Tibshirani R, Ciampi A, Till JE, Boyd NF. The measurement of patients' values in medicine. Med Decis Making. 1982;2:449-62.
42. Lenert LA, Morss S, Goldstein MK, Bergen MR, Faustman WO, Garber AM. Measurement of the validity of utility elicitations performed by computerized interview. Med Care. 1997;35:915-20.
43. Richardson J, Nord E. The importance of perspective in the measurement of quality-adjusted life years. Med Decis Making. 1997;17:23-31.
44. Luce MF, Bettman JR, Payne JW. Choice processing for emotionally difficult decisions. J Exp Psychol Learn, Mem, Cogn. 1997;23:384-405.